[ad_1]
1 hour ago
David Faber, CNBC, presents the latest news regarding the acquisition of Celgene by Bristol-Myers. In a press release, the company announced the convening of a special shareholders' meeting in April to decide on the Celgene deal. The hedge fund activist Starboard Value, which holds about $ 50 million worth of shares, announced that it had appointed five directors to the board of directors of the company for its annual meeting.
[ad_2]
Source link